Spectral AI (MDAI) Q2 FY26 earnings call

Spectral AI is transitioning from a development-stage company to a commercial organization following the landmark FDA de novo clearance for its DeepView System. The company is leveraging significant non-dilutive funding and strategic hires to execute a disciplined commercial launch, focusing on initial system placements and expanding its technology platform for new indications. While navigating initial commercialization hurdles, the company remains well-capitalized and focused on long-term growth.